February 24, 2020
1 min read

First-In-Human Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 1/phase 2, interventional, open-label study of the safety, tolerability and dose-limiting toxicities — and to determine a recommended phase 2 dose regimen — of REGN5459 as monotherapy for patients with relapsed or refractory multiple myeloma.